ImPact Biotech

A big thank you to Prof. Ronald Kaufman for leading the phase3 clinical trial #ENLIGHTED at Albany Medical College.   ImPact Biotech cutting-edge, #organ_sparing technology, #Padeliporfin #VTP therapy for patients with Low-Grade #UTUC (Upper Tract Urothelial Cancer), brings hope and improved quality of life to those in need.   Together, we’re shaping the future of healthcare! #innovation, #technology, #cancer, #urology, #minimallyinvasive, #QoL #clinicaltrial, Inna Krasnopolskaya, Evgenia (Genia) Alpert, Alexey Medvedchikov, MD, Dr. Eyal Morag, Barak Palatchi

Congrats to Dr. Sarah Psutka MD MSc at the University of Washington (UW) hospital, and thanks to Marielle Yano and the research team at UW CHORD (Center for Health Outcomes Research & Dissemination), who have initiated the #Padeliporfin #VTP therapy as part of ImPact Biotech phase 3 #ENLIGHTED clinical trial. #ENLIGHTED recruits patients with low-grade Upper Tract Urothelial Cancer (#UTUC), to be treated with #Padeliporfin #VTP (Vascular Targeted Photodynamic) therapy, aiming at preserving their kidney. Please visit the study website: https://lnkd.in/dr-qbcxp #clinicaltrial, #urology, #kidney, #photodynamictherapy, #cancer, #minimallyinvasive, Alexey Medvedchikov, MD, Inna Krasnopolskaya

What a great recognition by the European Innovation Council and SMEs Executive Agency (EISMEA) !!! 🎉 🎊 🎉 🎊 🎉 ImPact Biotech has been selected out of ‘000s of leading innovative companies to receive the #EUeic high recognition, and meaningful financing, of our #Padeliporfin Vascular Targeted Photodynamic (#VTP) therapy for the treatment of solid cancer tumors. Kudos to the ImPact team who persistently and successfully presented the company and our groundbreaking organ-sparing platform technology. #urology, #pancreaticcancer, #minimallyinvasive, #cancer, #photodynamictherapy, #innovative, #eicAccelerator, Barak Palatchi, Guy Schmidt, Dr. Eyal Morag, Roei Sella

🎥 Don't miss Zachary Klaassen conversation with Dr. Vitaly Margulis on the new and promising #Padeliporfin #VTP approach for the treatment of Upper Tract Urothelial Cancer (#UTUC), and our phase 3 #ELIGHTED trial.   📺 Watch Now: https://lnkd.in/dJaNk7Ez   For more info on ENLIGHTED, please visit the study website: https://lnkd.in/dr-qbcxp ImPact Biotech , #Urology, #minimallyinvasive, #cancer

We're thrilled to announce a groundbreaking milestone at Keck School of Medicine at USC Medical Center in Los Angeles, US.   Congratulations to Dr. Gerhard Fuchs, Dr. Hooman Djaladat, and the multidisciplinary team for their first patient treated in #ENLIGHTED clinical trial. ImPact Biotech phase 3 clinical trial #ENLIGHTED recruits patients with low-grade Upper Tract Urothelial Cancer (#UTUC), to be treated with #Padeliporfin #VTP (Vascular Targeted Photodynamic) therapy, aiming at preserving their kidney. For more info on ENLIGHTED, please visit the study website: https://lnkd.in/dr-qbcxp #Enlighted #clinicaltrial #urology #oncology #minimallyinvasive, Jerry Buentello, MD, Inna Krasnopolskaya, Alexey Medvedchikov, MD, Evgenia (Genia) Alpert, Dr. Eyal Morag, Guy Schmidt

Vitaly Margulis, M.D., Professor of Urology at UT Southwestern Medical Center, shares some of the impactful updates and advantages of #Padeliporfin #VTP in upper tract urothelial carcinoma (LG-#UTUC) presented following #ASCO24 Annual Meeting. #ENLIGHTED (https://lnkd.in/eAme2bT4) https://lnkd.in/eQBHBZJp

Congratulations to Prof. Rausch and his team at Universitätsklinikum Tübingen for being the first in Germany to administer our novel solution for low-grade urothelial cancer (#UTUC). Thank you for your dedication and groundbreaking work! For more info on ENLIGHTED, please visit the study website: https://lnkd.in/dr-qbcxp   ImPact Biotech #Enlighted #clinicaltrial #urology #oncology #minimallyinvasive #padeliporfin #VTP #patient, Universitätsklinikum Tübingen, Axelle MROZ, Inna Krasnopolskaya, Alexey Medvedchikov, MD, Evgenia (Genia) Alpert, Dr. Eyal Morag, Guy Schmidt

What a day at #ASCO24 !! We are excited to share the positive preliminary results from our Phase 3 ENLIGHTED trial, showcasing #Padeliporfin #VTP as a promising therapy for Low Grade Upper Tract Urothelial Cancer (LG-#UTUC). Look for our findings at ASCO Abstract 4622: https://lnkd.in/djJyyu7s Special thanks to Vitaly Margulis, Professor of Urology at UT Southwestern Medical Center, for his work in the trial and leading the abstract. #urology, #urooncology, #kidney, #ureter, #minimallyinvasive, ImPact Biotech , Dr. Eyal Morag, Barak Palatchi, Evgenia (Genia) Alpert, Inna Krasnopolskaya, Guy Schmidt

We’re here at #ASCO24! Bridging from Unresectable to Resectable LA-PDAC! Join our team at the first poster presentation, today, June 1, 2024, our Phase 1 study to evaluate safety and preliminary efficacy of #Padeliporfin vascular targeted photodynamic therapy (#VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (#PDAC): https://lnkd.in/d-rERfru 🔍 Poster Session & Primary Track: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. 🗓️ Date & Time: June 1, 2024, 1:30 PM-4:30 PM CDT. 📄 Abstract Number: 4204 🎤Abstract led by: Nadine Abi-Jaoudeh, Professor of Radiological Sciences at University of California, Irvine - College of Medicine ImPact Biotech Barak Palatchi, Dr. Eyal Morag, Evgenia (Genia) Alpert #pancreaticcancer, #minimallyinvasive, #Photodynamic

Are you on your way to Chicago for #ASCO24? ImPact Biotech invites you to join us for 2 poster presentations: -         Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. 6/1/2024, 1:30 PM-4:30 PM CDT. -         Genitourinary Cancer—Kidney and Bladder. 6/2/2024, 9:00 AM-12:00 PM CDT. Barak Palatchi, CEO, Dr. Eyal Morag, CMO, and Dr. Inna Krasnopolskaya, Head of Clinical Dev., as well as other great team members and key study investigators from the two clinical trials will be excited to elaborate on our impressive preliminary results from #ENLIGHTED ph3 in LG-UTUC and the coming ph1 clinical trial in Pancreatic Cancer See the full details of our poster presentations here: -         #ENLIGHTED phase 3 study: Efficacy and safety of #Padeliporfin vascular targeted photodynamic therapy (#VTP) for treatment of low-grade upper tract urothelial cancer (LG #UTUC): https://lnkd.in/djJyyu7s -         Phase 1 study to evaluate safety and preliminary efficacy of #Padeliporfin vascular targeted photodynamic therapy (#VTP) in patients with locally advanced (LA) unresectable pancreatic ductal adenocarcinoma (#PDAC): https://lnkd.in/d-rERfru We invite you to visit us for more info: www.impactbiotech.com Vitaly Margulis, Nadine Abi-Jaoudeh, Evgenia (Genia) Alpert, #urology, #pancreaticcancer, #minimallyinvasive, #innovation,